The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine

INTRODUCTION: The phase 3 PREEMPT trials demonstrated efficacy and tolerability of onabotulinumtoxinA for headache prevention in adults with chronic migraine. OnabotulinumtoxinA significantly reduced headache frequency from baseline vs. placebo at 24 weeks; however, this measure may not fully captur...

Descripción completa

Detalles Bibliográficos
Autores principales: Silberstein, Stephen D., Diener, Hans-Christoph, Dodick, David W., Manack Adams, Aubrey, DeGryse, Ronald E., Lipton, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648816/
https://www.ncbi.nlm.nih.gov/pubmed/33026630
http://dx.doi.org/10.1007/s40122-020-00199-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648816/
https://www.ncbi.nlm.nih.gov/pubmed/33026630
http://dx.doi.org/10.1007/s40122-020-00199-9

Ejemplares similares